Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age

NCT04070326 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT04070326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04070326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
August 19, 2019
Completion date
October 30, 2021
Enrollment
21 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema